The Motley FoolT3·1mo ago
AMLX Amylyx Pharmaceuticals, Inc. Common Stock
XNAS
27.09
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
AMLX
$27.09
—
Key stats
$27.09
Pre-market
$27.34
+0.92%
- 52-Week Range
- $10.83 – $41.14
- YTD
- +137.26%
- IV Rank (30D)
- 8.74
- Straddle Price
- $3.98
- P/C Vol Ratio
- 0.24
- Market Cap
- $3.4B
- Open
- $27.25
- Day Range
- $26.23 – $27.98
- Volume
- 1,371,105
- Prev Close
- $27.20
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.13% |
| Beta vs SPY | 1.04 |
| Cost of Equity (CAPM) | 10.86% (VRP-adj) |
| WACC | 10.87% |
| Volatility Risk Premium | +147.9pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -63.6% |
| Book / Price | 8.6% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $31.20 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $27.95 |
| Bollinger Width / SMA20 | 45.5% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $3B |
Peers used for multiples: JNJ, LLY, MANE, MRK, PFE, RPRX, VTRS, ZTS
60-Day Conviction
17%
20-Day Fair Value
≈ by Nov 24, 2026
$26.88
α -0.8%
rank 36%
conviction
47%
40-Day Fair Value
≈ by Dec 23, 2026
$27.26
α +0.6%
rank 36%
conviction
21%
60-Day Fair Value
≈ by Jan 21, 2027
$26.97
α -0.5%
rank 36%
conviction
17%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 40.0× · 6 peers |
| Peer EV/EBITDA | n/a | 0% | median 20.3× · 7 peers |
| Peer P/B | $18.45 | 28% | median 7.9× · 7 peers |
| Peer P/S | n/a | 0% | median 5.5× · 7 peers |
| Market Anchor (SMA50) | $31.20 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $27.24 | 72% | 41 strikes · skew +0.14 |
As of 2026-10-26 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $3.4B
- Employees
- 136
- List Date
- 2022-01-07
- CIK
- 0001658551
- Next Earnings
- 2026-11-05 (Pre-Market)
- EPS Forecast
- ($0.38) (4 est.)
- Headquarters
- Cambridge, MA
- Homepage
- https://www.amylyx.com
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | 28.28% | 8.92% | 6.88% | -6.65% | 25.13% | 12.51% |
| Feb | 40.84% | -11.60% | 13.76% | -4.09% | 3.41% | 8.46% |
| Mar | -54.17% | -14.24% | -84.82% | 18.00% | -9.15% | -28.88% |
| Apr | -30.12% | -0.73% | -33.21% | 52.99% | 11.50% | 0.09% |
| May | -2.63% | -13.34% | -10.88% | 0.19% | -10.37% | -7.41% |
| Jun | 125.26% | -11.78% | 11.76% | 25.69% | 27.65% | 35.72% |
| Jul | 38.62% | 11.83% | 9.57% | 25.27% | 13.34% | 19.73% |
| Aug | -2.21% | -7.78% | 7.25% | 21.58% | 67.33% | 17.23% |
| Sep | 19.58% | -16.09% | 50.00% | 36.17% | -13.93% | 15.15% |
| Oct | 19.90% | -9.99% | 76.47% | -0.50% | -3.53%* | 16.47% |
| Nov | 6.97% | -17.19% | -1.77% | 10.15% | -- | -0.46% |
| Dec | -5.88% | 3.52% | -31.89% | -15.17% | -- | -12.36% |
| Total | 148.34% | -58.16% | -74.45% | 292.46% | 136.16% | 88.87% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $27.81
SMA 50: $31.31
SMA 200: $19.77
Current: $27.09
EMA 12: $27.84
EMA 26: $28.51
MACD: -0.6720 | Signal: 0.0916
BEARISH
ADX (14): 20.77
WEAK TREND
+DI: 18.89
−DI: 30.20
Momentum Oscillators
RSI (14): 42.24
NEUTRAL
Stoch %K: 39.90
Stoch %D: 57.90
Williams %R: -73.48
Volume & Volatility
BB Upper: $29.39
BB Lower: $26.23
NEUTRAL
OBV: 75,116,593
Vol SMA 20: 1,346,409
Vol ROC: 23.96%
ATR: $1.46
True Range: $1.75
HV 20: 42.9%
HV 30: 45.5%
HV 60: 116.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
AMLX Stock Analysis Report
Executive Summary
Overall Assessment: BEARISH | Confidence Level: 7/10
Key Drivers & Primary Risks:
- Primary Driver: Strong long-term uptrend (247% YTD gain) supported by positive GLP-1 and ALS therapeutic market tailwinds
- Primary Risk: Technical breakdown in progress with price trading below all major moving averages amid bearish momentum signals
- Secondary Risk: Legal investigation alerts (July 2025) creating uncertainty despite positive news flow
Investment Thesis: AMLX presents a conflicting technical-fundamental picture: while the stock has benefited from favorable market narratives around GLP-1 therapeutics and ALS treatment expansion, current technical deterioration with price at $28.14 (7.2% below SMA 20 and 48.9% below SMA 200 despite the 247% gain) signals near-term downside risk. The bearish MACD crossover, elevated stochastic readings, and -DI dominating +DI (25.70 vs 17.77) suggest momentum has reversed despite bullish news sentiment.
Recent News Sentiment Impact: Mixed-to-positive aggregate sentiment (4/6 positive headlines), but critical timing issue: Legal investigation alerts from July 2025 appear to have coincided with technical deterioration. The positive news from September 2026 ("Is GLP-1 Stock Still a Buy") and market growth reports haven't arrested the current downtrend, suggesting price action has decoupled from headline sentiment—a bearish signal.
Technical Analysis
Trend Direction
- Short-term (1-4 weeks): BEARISH — Price decisively below SMA 20 ($30.20) and SMA 50 ($30.14); EMA 12 ($28.72) below EMA 26 ($29.68) confirms downtrend initiation
- Medium-term (1-3 months): NEUTRAL-TO-BEARISH — Stock transitioning from long-term uptrend but support structure intact; SMA 50 near SMA 20 suggests consolidation phase
- Long-term (3-12 months): BULLISH — SMA 200 at $18.91 represents strong uptrend foundation; price 48.9% above 200-day average despite recent pullback
Interpretation: Stock is in corrective phase within primary uptrend. The 247% YTD gain likely established euphoric conditions; current pullback may be healthy consolidation or early reversal signal.
Support/Resistance Levels
| Level | Type | Distance | Implication | |-------|------|----------|-------------| | $34.73 | Resistance (BB Upper) | +23.4% above current | Strong overhead resistance | | $30.20 | Resistance (SMA 20) | +7.2% above current | Key near-term hurdle | | $28.14 | Current Price | — | Testing downside pressure | | $25.68 | Support (BB Lower) | -8.8% below current | Critical support level | | $25.00 | Psychological | -11.2% below current | Potential support cluster | | $18.91 | Support (SMA 200) | -32.8% below current | Absolute long-term floor |
Critical Observation: Price is dangerously close to Bollinger Band lower boundary ($25.68), only 8.8% away. A break below this level would signal potential acceleration of downtrend and test of psychological $25.00 level.
Momentum Signals
RSI (14): 41.58 — NEUTRAL with bearish bias
- Reading in neutral zone (30-70) but closer to oversold territory (<30)
- Not yet oversold enough to trigger typical mean-reversion buy signal
- Suggests further downside possible before capitulation reversal
- If RSI breaks below 30, would signal extreme oversold condition
MACD: -0.97 / Signal: -0.42 / Histogram: -0.54 — BEARISH CROSSOVER
- MACD (-0.97) below signal line (-0.42) confirms bearish momentum
- Negative histogram (-0.54) indicates bearish momentum is strengthening
- Critical Signal: MACD has not yet shown reversal/bullish crossover—downtrend momentum still accelerating
- A bullish MACD crossover would be first confirmation of reversal
Stochastic Oscillators: %K 17.19, %D 12.70 — EXTREMELY OVERSOLD
- Both %K and %D in extreme oversold territory (<20 is extreme)
- Williams %R -70.63: Confirms extreme oversold conditions
- This level typically precedes short-term bounces, but given MACD weakness, may indicate capitulation rather than reversal
- Watch for stochastic to cross above 20 for technical reversal confirmation
Bollinger Bands: 29.99 width — NEUTRAL (slightly expanding)
- Band width neither squeezed nor excessively wide
- Price approaching lower band suggests mean-reversion pressure
- Historically, when price touches lower BB, expect reversion toward middle ($30.20)
Volume Analysis
Volume Indicators:
- Volume SMA (20): 1,491,635 shares—establishing baseline
- Volume Rate of Change: +13.67%—increasing volume on downside moves (bearish sign)
- On-Balance Volume: 82,018,895 (positive but need trend direction)
Interpretation: Volume increase during downward price move suggests distribution by institutional holders or capitulation selling. Combined with positive IV Premium (+22.5%), this suggests options market is pricing in continued volatility despite news sentiment.
Institutional Interest Signal: Volume flowing into the downside with elevated ROC indicates institutional participation in selling/shorting, not typical retail panic. This is more concerning than retail-driven sell-off.
News & Sentiment Analysis
Recent Headlines Summary
| Theme | Headlines | Sentiment | Timing | |-------|-----------|-----------|--------| | GLP-1/Market Tailwinds | "Is GLP-1 Stock Still a Buy," ALS market growth forecasts | POSITIVE (2) | Sept 2026, Feb 2026 | | Pipeline/Therapeutics | Antisense oligonucleotide pipeline robustness | POSITIVE (1) | Aug 2025 | | Legal/Regulatory | Bragar Eagel & Squire investigation alerts | NEGATIVE (2) | July 2025 (2x) | | General Positive | "Stock Was So Healthy This Week" | POSITIVE (1) | Oct 2024 |
Positive Themes (4/6):
- GLP-1 market expansion narrative supports long-term thesis
- ALS therapeutic market projected to reach $1.964B by 2035 (11.5% CAGR)
- Robust pipeline activity in antisense oligonucleotide domain
- Recent positive general commentary
Negative Themes (2/6):
- Class action investigation by Bragar Eagel & Squire (repeated alerts suggest ongoing issue)
- Investigation focus on "long-term stockholders" implies potential shareholder claim
Sentiment Assessment: MIXED-TO-POSITIVE (Aggregate +3 net)
- News sentiment should be supportive, yet price declined significantly
- Critical Conflict: Positive headlines from Sept 2026 and Feb 2026 haven't halted downtrend, suggesting:
- News is already priced in from 247% YTM move
- Legal investigation creates overhang offsetting positive therapeutics narrative
- Market prioritizing near-term legal/regulatory risk over long-term market growth
Catalyst Identification
Immediate (1-7 days):
- Legal investigation outcome/resolution (Bragar Eagel investigation status)
- No earnings date provided—DATA GAP FLAGGED
Near-term (1-4 weeks):
- Technical reversal signals (MACD bullish crossover, RSI break above 40)
- Any regulatory updates on ALS therapeutic development
- Options expiration (42 DTE from analysis date)
Medium-term (1-3 months):
- ALS therapeutic pipeline milestones
- GLP-1 market dynamics and competitive positioning
- Earnings release (date not provided—CRITICAL DATA GAP)
Market Narrative Assessment
Narrative Disconnect: The strong positive headlines don't align with technical deterioration. This divergence is a significant red flag. Typical scenarios: 1
Generated
News
All AMLX news →
GlobeNewswire Inc.T3·8mo ago
GlobeNewswire Inc.T3·14mo ago
GlobeNewswire Inc.T3·15mo ago
GlobeNewswire Inc.T3·15mo ago
The Motley FoolT3·24mo ago
BenzingaT3·29mo ago
Zacks Investment ResearchT3·30mo ago
Zacks Investment ResearchT3·30mo ago
Zacks Investment ResearchT3·30mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
16 of 17 under expected move
Avg Expected Move
17.76%
Avg Actual Move
6.48%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-08-11 | Pre-Market | 44.13% | 1.92% | 0.04x | Within |
| 2022-11-10 | Pre-Market | 11.21% | 2.25% | 0.20x | Within |
| 2023-03-13 | Pre-Market | 19.05% | 1.66% | 0.09x | Within |
| 2023-05-11 | Pre-Market | 12.51% | 0.41% | 0.03x | Within |
| 2023-08-10 | Pre-Market | 15.82% | 1.49% | 0.09x | Within |
| 2023-11-09 | Pre-Market | 12.11% | 31.89% | 2.63x | Exceeded |
| 2024-02-22 | Pre-Market | 23.06% | 21.10% | 0.92x | Within |
| 2024-05-09 | Pre-Market | 14.51% | 2.07% | 0.14x | Within |
| 2024-08-08 | Pre-Market | 13.30% | 4.26% | 0.32x | Within |
| 2024-11-07 | Pre-Market | 12.86% | 5.14% | 0.40x | Within |
| 2025-03-04 | Pre-Market | 15.83% | 0.33% | 0.02x | Within |
| 2025-05-08 | Pre-Market | 15.40% | 5.95% | 0.39x | Within |
| 2025-08-07 | Pre-Market | 16.48% | 4.27% | 0.26x | Within |
| 2025-11-06 | Pre-Market | 20.02% | 5.89% | 0.29x | Within |
| 2026-03-03 | Pre-Market | 16.99% | 7.78% | 0.46x | Within |
| 2026-05-07 | After-Close | 7.89% | 3.09% | 0.39x | Within |
| 2026-08-06 | Pre-Market | 30.78% | 10.71% | 0.35x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
AMLX Options Activity & IV Rank
AMLX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 64.7%
7-DTE IV: —
Expected Move: $3.98
7-DTE Move: $3.98
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 561
Put Volume: 135
P/C Volume: 0.241
BULLISH
Call OI: 3,073
Put OI: 1,354
P/C OI: 0.441
Total OI: 4,427
ATM Options Pricing
ATM Call: $2.10
ATM Put: $1.88
Call %: 7.8%
Put %: 6.9%
Chain Summary
Chain Volume: 3,097
Chain OI: 15,856
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 93rd percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
93%
vs own history
GEX tilt
+0.44
OI-weighted, today
Vanna tilt
+0.33
δ-sensitivity to IV
Charm tilt
-0.39
δ-decay vs time
Vanna tilt +0.33: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.39: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 21 ATM contracts, 4k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 70.5% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)8.7LowOct 26
Straddle Price (30 DTE)$3.98Oct 26
Beta Analysis
Risk Metrics
Beta: 0.9174
Alpha: 84.34%
Correlation: 0.1350
R-Squared: 1.8%
Stock Volatility: 86.6%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
AMLX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 102,414,685 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
10 filers$12.00M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $7.28M | 60.68% | 2026-06-30 |
| 2 | 683 Capital Management, LLC | $1.73M | 14.46% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $1.69M | 14.09% | 2026-06-30 |
| 4 | Wolverine Trading, LLC Custodian | $408.26K | 3.40% | 2025-09-30 |
| 5 | Jane Street Group, LLC Custodian | $314.30K | 2.62% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $251.44K | 2.10% | 2026-06-30 |
| 7 | Tetragon Partners GP Ltd | $152.66K | 1.27% | 2026-06-30 |
| 8 | Point72 Asset Management, L.P. | $147.27K | 1.23% | 2026-06-30 |
| 9 | Walleye Capital LLC | $16.16K | 0.13% | 2026-06-30 |
| 10 | Caption Management, LLC | $1.80K | 0.01% | 2026-06-30 |
9 filers$2.96M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $1.08M | 36.45% | 2026-06-30 |
| 2 | ADAR1 Capital Management, LLC | $720.20K | 24.32% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $578.31K | 19.53% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $192.17K | 6.49% | 2026-06-30 |
| 5 | Point72 Asset Management, L.P. | $136.50K | 4.61% | 2026-06-30 |
| 6 | Walleye Capital LLC | $118.54K | 4.00% | 2026-06-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $109.56K | 3.70% | 2026-06-30 |
| 8 | Caption Management, LLC | $14.37K | 0.49% | 2026-06-30 |
| 9 | Simplex Trading, LLC Custodian | $12.57K | 0.42% | 2026-06-30 |
AMLX Insider Trading (Form 4)
Latest: 2026-10-07Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | George M Milne Jr | Director | Sell (S) | −30,000 | $27.70 | -$830.9K | EDGAR |
| 2026-09-14 | Camille L Bedrosian | Chief Medical Officer | Sell (S) | −10,028 | $32.40 | -$324.9K | EDGAR |
| 2026-09-14 | Gina Mazzariello | Chief Legal Officer | Sell (S) | −9,536 | $32.46 | -$309.5K | EDGAR |
| 2026-09-14 | Justin B. Klee | Co-Chief Executive Officer | Sell (S) | −30,464 | $32.18 | -$980.3K | EDGAR |
| 2026-09-14 | Joshua B Cohen | Co-Chief Executive Officer | Sell (S) | −30,464 | $32.19 | -$980.5K | EDGAR |
| 2026-09-14 | James M Frates | Chief Financial Officer | Sell (S) | −10,810 | $32.36 | -$349.8K | EDGAR |
| 2026-09-02 | Karen Firestone | Director | Exer (M) | +50,000 | $3.40 | $170.2K | EDGAR |
| 2026-08-20 | Justin B. Klee | Co-Chief Executive Officer | Award (A) | +60,039 | — | EDGAR | |
| 2026-08-20 | Camille L Bedrosian | Chief Medical Officer | Award (A) | +22,807 | — | EDGAR | |
| 2026-08-20 | Joshua B Cohen | Co-Chief Executive Officer | Award (A) | +60,039 | — | EDGAR | |
| 2026-08-20 | Gina Mazzariello | Chief Legal Officer | Award (A) | +21,284 | — | EDGAR | |
| 2026-08-20 | James M Frates | Chief Financial Officer | Award (A) | +22,807 | — | EDGAR | |
| 2026-07-13 | Gina Mazzariello | Chief Legal Officer | Sell (S) | −30,000 | $17.96 | -$538.9K | EDGAR |
| 2026-06-08 | George M Milne Jr | Director | Grant (A) | +24,372 opt | — | EDGAR | |
| 2026-06-08 | Bernhardt G Zeiher | Director | Grant (A) | +24,372 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
AMLX Insider Holdings
10 insiders · @ $27.09
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Joshua B Cohen | Co-Chief Executive Officer | 3,614,042 | $97.90M | -$7.39M | 25 | 2026-09-14 |
| 2 | Justin B. Klee | Co-Chief Executive Officer | 3,613,056 | $97.88M | -$7.39M | 24 | 2026-09-14 |
| 3 | George M Milne Jr | Director | 782,881 | $21.21M | -$1.23M | 13 | 2026-10-07 |
| 4 | James M Frates | Chief Financial Officer | 333,625 | $9.04M | -$3.57M | 25 | 2026-09-14 |
| 5 | Camille L Bedrosian | Chief Medical Officer | 278,064 | $7.53M | -$798.7K | 12 | 2026-09-14 |
| 6 | Gina Mazzariello | Chief Legal Officer | 190,849 | $5.17M | -$1.87M | 26 | 2026-09-14 |
| 7 | Karen Firestone | Director | 91,900 | $2.49M | $350.6K | 10 | 2026-09-02 |
| 8 | Bernhardt G Zeiher | Director | 10,000 | $270.9K | $37.0K | 5 | 2026-06-08 |
| 9 | Paul R. Fonteyne | Director | 3,947 | $106.9K | $75.0K | 6 | 2026-06-08 |
| 10 | Daphne Quimi | Director | 2,750 | $74.5K | $9.4K | 7 | 2026-06-08 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
AMLX Board & Officers
As of SEC filings through Oct 7, 2026Directors 7
- Daphne Quimi · since Jan 6, 2022
- George M Milne Jr · since Jan 6, 2022
- Joshua B Cohen · since Jan 6, 2022
- Justin B. Klee · since Jan 6, 2022
- Paul R. Fonteyne · since Jan 6, 2022
- Karen Firestone · since Mar 16, 2023
- Bernhardt G Zeiher · since Mar 14, 2024
Officers 5
- Joshua B Cohen · Co-Chief Executive Officer · since Jan 6, 2022
- Justin B. Klee · Co-Chief Executive Officer · since Jan 6, 2022
- James M Frates · Chief Financial Officer · since Jan 6, 2022
- Gina Mazzariello · Chief Legal Officer · since Feb 22, 2022
- Camille L Bedrosian · Chief Medical Officer · since Nov 27, 2023
Changes in the last 10 years (39)
| Mar 14, 2024 | Bernhardt G Zeiher became a director |
| Nov 27, 2023 | Camille L Bedrosian became Chief Medical Officer |
| Aug 17, 2023 | Morningside Venture Investments Ltd reported in an SEC filing no longer being a 10% owner |
| Mar 16, 2023 | Karen Firestone became a director |
| Nov 1, 2022 | The company announced the departure of Isaac Cheng from the board in an SEC filing |
| Sep 9, 2022 | Viking Global Opportunities Portfolio GP LLC reported in an SEC filing no longer being a 10% owner |
| Sep 9, 2022 | Viking Global Opportunities Parent GP LLC reported in an SEC filing no longer being a 10% owner |
| Sep 9, 2022 | Viking Global Opportunities Illiquid Investments Sub-Master LP reported in an SEC filing no longer being a 10% owner |
| Sep 9, 2022 | Viking Global Opportunities GP LLC reported in an SEC filing no longer being a 10% owner |
| Sep 9, 2022 | Viking Global Investors LP reported in an SEC filing no longer being a 10% owner |
| Sep 9, 2022 | Rose Sharon Shabet reported in an SEC filing no longer being a 10% owner |
| Sep 9, 2022 | Ole Andreas Halvorsen reported in an SEC filing no longer being a 10% owner |
| Sep 9, 2022 | Dragsa 96 LLC reported in an SEC filing no longer being a 10% owner |
| Sep 9, 2022 | David C. Ott reported in an SEC filing no longer being a 10% owner |
| Jul 8, 2022 | ALS Invest 1 B.V. reported in an SEC filing no longer being a 10% owner |
| Feb 22, 2022 | Gina Mazzariello became Chief Legal Officer |
| Jan 11, 2022 | Dragsa 96 LLC became a 10% owner |
| Jan 6, 2022 | Viking Global Opportunities Portfolio GP LLC became a 10% owner |
| Jan 6, 2022 | Viking Global Opportunities Parent GP LLC became a 10% owner |
| Jan 6, 2022 | Viking Global Opportunities Illiquid Investments Sub-Master LP became a 10% owner |
| Jan 6, 2022 | Viking Global Opportunities GP LLC became a 10% owner |
| Jan 6, 2022 | Viking Global Investors LP became a 10% owner |
| Jan 6, 2022 | Rose Sharon Shabet became a 10% owner |
| Jan 6, 2022 | Paul R. Fonteyne became a director |
| Jan 6, 2022 | Patrick D Yeramian became Chief Medical Officer |
| Jan 6, 2022 | Ole Andreas Halvorsen became a 10% owner |
| Jan 6, 2022 | Mvil, LLC became a 10% owner |
| Jan 6, 2022 | Morningside Venture Investments Ltd became a 10% owner |
| Jan 6, 2022 | Margaret Olinger became Chief Commercial Officer |
| Jan 6, 2022 | Justin B. Klee became a director |
| Jan 6, 2022 | Justin B. Klee became Co-Chief Executive Officer |
| Jan 6, 2022 | Joshua B Cohen became a director |
| Jan 6, 2022 | Joshua B Cohen became Co-Chief Executive Officer |
| Jan 6, 2022 | James M Frates became Chief Financial Officer |
| Jan 6, 2022 | Isaac Cheng became a director |
| Jan 6, 2022 | George M Milne Jr became a director |
| Jan 6, 2022 | David C. Ott became a 10% owner |
| Jan 6, 2022 | Daphne Quimi became a director |
| Jan 6, 2022 | ALS Invest 1 B.V. became a 10% owner |
Not reported recently (3)
- Patrick D Yeramian · Last reported as Chief Medical Officer in an SEC filing dated Jan 11, 2024
- Margaret Olinger · Last reported as Chief Commercial Officer in an SEC filing dated Dec 29, 2023
- Mvil, LLC · Last reported as a 10% owner in an SEC filing dated Mar 17, 2022
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
AMLX Proposed Insider Sales (Form 144)
Latest: 2026-10-05
? Form 144 Guide
Last 30d:
1 filing
· $2.8M notice value
· Last 90d:
6 filings
· $5.7M notice value
· 6 unique filers
· 17% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
GEORGE MILNE (1, $2.8M) · Cohen Joshua B (1, $981K) · Klee Justin B. (1, $980K) · Frates James M (1, $350K) · Bedrosian Camille L (1, $325K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-05 | GEORGE MILNE | Director | 100,000 | $2.78M | 2026-10-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-11 | Klee Justin B. | Officer, Director | 30,464 | $980.3K | 2026-09-10 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-09-11 | Frates James M | Officer | 10,810 | $349.8K | 2026-09-10 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-09-11 | Bedrosian Camille L | Officer | 10,028 | $324.9K | 2026-09-10 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-09-11 | Mazzariello Gina | Officer | 9,536 | $309.5K | 2026-09-10 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-09-11 | Cohen Joshua B | Officer, Director | 30,464 | $980.5K | 2026-09-10 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-07-09 | GINA MAZZARIELLO | Officer | 30,000 | $536.4K | 2026-07-09 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-02 | Mazzariello Gina | Officer | 6,844 | $99.4K | 2026-03-02 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-03-02 | Cohen Joshua B | Officer, Director | 29,282 | $424.1K | 2026-03-02 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-03-02 | Klee Justin B. | Officer, Director | 29,282 | $423.8K | 2026-03-02 | Morgan Stanley Smith Barney LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
57 ETFs hold AMLX
25 shown · $342.70M total exposure · 0.07% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $110.6M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.10% | $71.1M | $74.6B | 2026-10-23 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.04% | $33.6M | — | 2026-09-30 |
| 4 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.19% | $26.3M | $13.7B | 2026-10-23 |
| 5 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.21% | $22.0M | $10.7B | 2026-10-23 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.10% | $17.5M | — | 2026-09-30 |
| 7 | IHE iShares U.S. Pharmaceuticals ETF | iShares (BlackRock) | 0.61% | $9.4M | $1.5B | 2026-10-23 |
| 8 | VHT Vanguard Health Care ETF | Vanguard | 0.04% | $7.8M | — | 2026-09-30 |
| 9 | XPH State Street® SPDR® S&P® Pharmaceuticals ETF | SPDR (State Street) | 1.73% | $7.6M | $439.0M | 2026-10-23 |
| 10 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.03% | $5.8M | — | 2026-05-31 |
| 11 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $3.8M | $96.5B | 2026-10-23 |
| 12 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.20% | $3.3M | — | 2026-09-30 |
| 13 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.17% | $3.2M | — | 2026-10-23 |
| 14 | FNY First Trust Mid Cap Growth AlphaDEX® Fund | First Trust | 0.56% | $3.1M | $542.0M | 2026-10-23 |
| 15 | FNX First Trust Mid Cap Core AlphaDEX® Fund | First Trust | 0.20% | $2.7M | $1.4B | 2026-10-23 |
| 16 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.06% | $2.4M | $4.2B | 2026-10-23 |
| 17 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.06% | $1.7M | — | 2026-07-31 |
| 18 | FFSM Fidelity Fundamental Small-Mid Cap ETF | Nport | 0.11% | $1.7M | — | 2026-07-31 |
| 19 | SBIO ALPS Medical Breakthroughs ETF | Nport | 1.01% | $1.6M | — | 2026-05-31 |
| 20 | NUSC Nuveen ESG Small-Cap ETF | Nport | 0.11% | $1.4M | — | 2026-07-31 |
| 21 | ESML iShares ESG Aware MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.05% | $1.4M | $2.7B | 2026-10-23 |
| 22 | RSSL Global X Russell 2000 ETF | Global X | 0.09% | $1.4M | — | 2026-10-26 |
| 23 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.03% | $1.2M | $3.8B | 2026-10-23 |
| 24 | FAD First Trust Multi Cap Growth AlphaDEX® Fund | First Trust | 0.17% | $1.0M | $590.1M | 2026-10-23 |
| 25 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.09% | $928,581 | $1.0B | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.41
TTM Revenue
—
TTM Net Income
$-152.09M
TTM Op. Cash Flow
$-126.58M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-43.42M | $-0.39 | $-31.42M |
| Q1 '26 | 2026-03-31 | — | $-41.28M | $-0.37 | $-36.88M |
| Q4 '25 | 2025-12-31 | — | $-33.00M | $-0.28 | $-27.90M |
| Q3 '25 | 2025-09-30 | — | $-34.39M | $-0.37 | $-30.37M |
| Q2 '25 | 2025-06-30 | — | $-41.44M | $-0.46 | $-25.25M |
| Q1 '25 | 2025-03-31 | — | $-35.91M | $-0.42 | $-39.82M |
| Q4 '24 | 2024-12-31 | $-665.00K | $-37.55M | $-0.54 | $-59.01M |
| Q3 '24 | 2024-09-30 | $416.00K | $-72.70M | $-1.07 | $-41.57M |
| Q2 '24 | 2024-06-30 | $-1.02M | $-72.70M | $-1.07 | $-66.58M |
| Q1 '24 | 2024-03-31 | $88.64M | $-118.79M | $-1.75 | $-489.00K |
| Q4 '23 | 2023-12-31 | $108.45M | $4.73M | $0.07 | $13.55M |
| Q3 '23 | 2023-09-30 | $102.69M | $20.89M | $0.30 | $-5.17M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
11.60
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-63.6%
ROA
-57.5%
Div Yield
0.00%
FCF Yield
-4.56%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$2.77B
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
12.67M
SI % of Float
13.14%
Days to Cover
9.16
Short Vol Ratio
60.3%
Free Float
96.37M
Float %
86.5%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-07